MASH as an emerging cause of hepatocellular carcinoma: current knowledge and future perspectives
Molecular Oncology · 2025-02 · 19 (2) · 275-294
DOI: 10.1002/1878-0261.13685 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Oncology, online erschienen am 14.06.2024. Verfasst von Michael Karin und 1 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Gene Regulation and Signal Transduction, Departments of Pharmacology and Pathology, School of Medicine, University of California San Di…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 225 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, Hanyang University, Prevent Cancer Foundation.
Abstract (Originalsprache)
Hepatocellular carcinoma is one of the deadliest and fastest‐growing cancers. Among HCC etiologies, metabolic dysfunction‐associated fatty liver disease (MAFLD) has served as a major HCC driver due to its great potential for increasing cirrhosis. The obesogenic environment fosters a positive energy balance and results in a continuous rise of obesity and metabolic syndrome. However, it is difficult to understand how metabolic complications lead to the poor prognosis of liver diseases and which molecular mechanisms are underpinning MAFLD‐driven HCC development. Thus, suitable preclinical models that recapitulate human etiologies are essentially required. Numerous preclinical models have been created but not many mimicked anthropometric measures and the course of disease progression shown in the patients. Here we review the literature on adipose tissues, liver‐related HCC etiologies and recently discovered genetic mutation signatures found in MAFLD‐driven HCC patients. We also critically review current rodent models suggested for MAFLD‐driven HCC study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratory of Gene Regulation and Signal Transduction, Departments of Pharmacology and Pathology, School of Medicine, University of California San Diego, La Jolla, CA, USA.
- Department of Molecular and Life Science, Hanyang University ERICA, Ansan, Korea.
ORCID-Profile: Michael Karin, Ju Youn Kim
Förderung
- NIDDK NIH HHS
- Hanyang University
- Prevent Cancer Foundation
- NIH HHS
- Korea National Institute of Health
- National Institutes of Health
Zitieren
APA
Karin, M., & Kim, J. Y. (2025). MASH as an emerging cause of hepatocellular carcinoma: current knowledge and future perspectives. Molecular Oncology, 19(2), 275-294. https://doi.org/10.1002/1878-0261.13685
Vancouver
Karin M, Kim JY. MASH as an emerging cause of hepatocellular carcinoma: current knowledge and future perspectives. Molecular Oncology. 2025;19(2):275-294. doi:10.1002/1878-0261.13685
BibTeX
@article{Karin2025,
author = {Karin, Michael and Kim, Ju Youn},
title = {MASH as an emerging cause of hepatocellular carcinoma: current knowledge and future perspectives},
journal = {Molecular Oncology},
year = {2025},
volume = {19},
number = {2},
pages = {275--294},
doi = {10.1002/1878-0261.13685}
}
EUVIMED